OK HB2665

Amends 63 O.S. 2011, Section 2-309D relating to the Anti-Drug Diversion Act to authorize additional disclosure of prescription monitoring program information

Allows the Director of the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control to disclose prescription monitoring program information to other states' prescription monitoring programs under reciprocal data-sharing agreements

Maintains strict confidentiality restrictions on nonfatal overdose information, limiting access to the Director or designee, the Chief Medical Examiner, and the registrant who entered the information

Clarifies that registrants have no requirement to access the central repository prior to dispensing medications and are not liable for damages resulting from accessing or failing to access the information

Takes effect November 1, 2014